Mergermarket’s year-end Global & Regional M&A Report places Goodwin among the top legal advisors on deals around the world. The results, reflecting transactions from 2017, demonstrate the firm’s deep bench in Technology, Real Estate, Life Sciences, and Private Equity across all geographies and sectors.
Goodwin was highly ranked in the following categories:
- #2 Global and U.S. private equity exits (up 8 and 4 spots, respectively)
- #2 U.S. private equity buyouts + exits (up 8 spots)
- #3 Global private equity buyouts + exits (up 10 spots)
- #4 France M&A deals (up 25 spots)
- #5 U.S. M&A deals (up 8 spots)
- #6 Global M&A deals (up 23 spots)
- #7 Europe buyouts (up 26 spots)
- #10 Europe buyouts + exits (up 44 spots)
With more than 180 lawyers, Goodwin’s Technology Companies practice is consistently rated in the top five most active of all law firms for venture capital, IPOs and M&A. The practice supports clients at all stages of the corporate life cycle with legal advisory related to company formation, IP protection, licensing, commercial agreements and venture financing to IPOs, M&A, corporate governance, board matters and more. The practice also represents a number of leading venture capital firms on fund formation, investments and other matters.
The firm’s Real Estate Industry lawyers are known globally for offering clients a practical approach to their investment decisions – from private fund formation and all types of real estate transactions to REIT and real estate M&A. The team helps to structure, negotiate and close complex public and private equity and debt financings, joint ventures, portfolio and REIT M&A, cross-border transactions, hospitality and leisure deals, and large-scale development work. Goodwin’s Real Estate Industry practice was ranked first in the 2017 edition of Commercial Property Executive’s Leading Real Estate Law Firms.
Goodwin’s Life Sciences practice was recently named “Practice Group of the Year” by Law360, which called the firm “a top choice for high-profile pharmaceutical clients, particularly in licensing deals, mergers and acquisitions, and initial public offerings.” Goodwin has been consistently recognized by U.S. News and World Report - Best Lawyers as “Biotech Firm of Year,” including in 2017.
The firm’s internationally recognized Private Equity practice focuses on buyouts, recapitalizations, growth equity investments, and portfolio company transactions in the U.S. and internationally with a leading position in the U.S. middle markets and growth equity. With a team of over 200 lawyers, the practice covers the full life cycle of clients’ investments – from fund formation to exit and everything in between.